A blind spot in urology: Prostate cancer associated retinopathy

Duncan, Catriona; Zamir, Ehud; Teh, Jiasian; Joon, Daryl Lim; Liodakis, Peter

doi:10.1016/j.eucr.2019.100872

Cited by 5 publications

(5 citation statements)

References 5 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10,11 An interesting cause of the diminution of vision was reported by Duncan et al as retinopathy as a paraneoplastic manifestation of prostatic carcinoma. 12 The present case was similar to that described by Malloy, with prostate cancer metastasis to the clivus and presentation of deficit in eye abduction and sixth cranial nerve involvement. Neuroimaging in the Malloy case revealed metastasis to the clivus, involvement of the cavernous sinus and smaller metastasis to the left temporal lobe with extensive bony involvement in the vertebral column.…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

Blindness paving the path to the diagnosis of metastatic prostate carcinoma: A unique case presentation

Jain

Nayan

Patwardhan

2021

Journal of Clinical Urology

View full text Add to dashboard Cite

Background: Intracranial metastases from prostate adenocarcinoma are very unusual and typically occur late in the course of the disease, and initial presentation with symptomatic brain involvement, especially vision loss is very rare (with this being only the sixth such reported case to the best of our knowledge). The present case elucidates how a diagnosis was reached in such a scenario and the management provided. Case presentation: A 66-year-old gentleman presented with loss of vision and headache with no other ocular or neurological complaint. Computed tomography (CT) of his head revealed a destructive lesion involving the clivus and a space-occupying lesion (SOL) in occipito-parietal region. Detailed inquiry regarding the possible primary source of suspected the metastatic lesion revealed an increased frequency of urination, nocturia, and significant weight loss. His serum prostate-specific antigen (PSA) levels were raised. He was treated by surgical hormonal therapy and his visual symptoms improved. Conclusion: Awareness of such a presentation can lead to an accurate diagnosis. Initiation of appropriate therapy can successfully alleviate the neurologic deficits.

show abstract

Section: Discussionsupporting

confidence: 87%

“…10,11 An interesting cause of the diminution of vision was reported by Duncan et al as retinopathy as a paraneoplastic manifestation of prostatic carcinoma. 12…”

Section: Discussionmentioning

confidence: 99%

Blindness paving the path to the diagnosis of metastatic prostate carcinoma: A unique case presentation

Jain

Nayan

Patwardhan

2021

Journal of Clinical Urology

View full text Add to dashboard Cite

show abstract

“…It is difficult to ascertain the etiology of AIR to determine whether cancer preceding AIR caused the autoantibody formation or the autoantibody formation occurred prior to and independent of any malignancy. However, these authors speculate that regardless of AIR occurring before or after the diagnosis of a malignancy, a likely subclinical malignancy must have been present that remained undetected until advancing to further stages to manifest signs and symptoms or perturbations on labs and imaging [7,64,87].…”

Section: Discussionmentioning

confidence: 99%

Review of Autoimmune Retinopathy and Its Association with Melanoma and Other Malignancies

Klepper

2023

JDR

View full text Add to dashboard Cite

Autoimmune Retinopathy (AIR) is an immune-mediated degenerative retinal disorder affecting retinal cell function leading to progressive vision loss. This review aims to quantify documented AIR cases in the literature; and elucidate common visual symptoms, AIR and cancer diagnosis chronology and autoantibodies’ role in AIR pathophysiology. A literature search extracted 58 Melanoma-Associated Retinopathy (MAR) and 76 Cancer-Associated Retinopathy (CAR) cases; CAR primarily consisted of lung, endometrial, ovarian and breast cancer. The majority of MAR cases presented with a melanoma diagnosis preceding onset of AIR symptoms, while the majority of CAR cases presented with AIR symptoms preceding the diagnosis of malignancy. MAR patients experienced nyctalopia and photopsias while CAR patients experienced vision loss, photopsias and nyctalopia. Anti-recoverin is the most well-established antibody implicated in AIR pathogenicity. However, autoantibodies to α-enolase, aldolase A and C, transducin-α, carbonic anhydrase II, arrestin, GAPDH and Transient Receptor Potential cation channel, subfamily M, member 1 (TRPM1) are also key components of retinal degeneration. AIR is likely caused by antibodies-targeting retinal antigens aberrantly expressed in cancer cells-penetrating the blood-retinal barrier and cross-reacting with retinal cell antigens, inducing retinal pathology. It may be appropriate to include AIR vision panel screening as standard of care for individuals with personal/family history or signs/symptoms of retinopathy or cancers for early detection and intervention.

show abstract

“…Patients who presented with optic canal metastases at their initial presentation were more likely to receive ocular surgical interventions, likely to help reach a diagnosis. It should be noted that diagnosing PCa in these scenarios can be challenging, as PSA can be expected, as was the case for four patients in this study who were undergoing treatment for their PCa [ 6 , 7 , 11 , 24 ]. The median time-to-death from ocular metastasis from PCa was 22 (range: 2-84) months.…”

Section: Reviewmentioning

confidence: 99%

Metastatic Prostate Cancer to the Optic Canal: A Large-Cohort Analysis

Kelkar,

Findakly,

Wang

2023

Cureus

View full text Add to dashboard Cite

Prostate cancer (PCa) can present with metastases in rare cases, including those to the optic canal. Currently, no guidelines exist for managing PCa metastases in this patient population. This article aims to examine optic canal metastases through a large-cohort analysis. It involves a systematic review of the literature through a pooled analysis of published cases of PCa with optic canal or orbital metastasis, including one case previously reported from our institution. A subgroup analysis was employed to compare cases with optic metastases as their initial PCa presentation, hormone-naive (HN), versus those with optic metastases after PCa diagnosis, hormone-refractory (HR). A total of 45 patients with ocular metastasis from PCa were included in this study. The mean age at diagnosis overall was 66.8 years (range: 45-85 years). Moreover, 16 cases (50%) had deceased, with a median time-to-death of 22 (range: 2-84) months. Regarding subgroup analysis, the mean age at diagnosis was 69.5 years (53-85 years) in the HN group and 64.5 years (45-83 years) in the HR group. With regard to reported survival, 10 (62.5%) cases belonged to the HN subset with a median follow-up duration of 12 (range: 1.5-36) months. In terms of reported mortality, 10 (62.5%) were from the HR subset with a median time-to-death of 32.5 (range 0.5-84) months. Our study constitutes the largest and most comprehensive examination of patients with optic canal metastases due to PCa so far. While optic canal metastases are a rare manifestation of PCa, they are linked with a poor prognosis. We also observed significant differences between HR and HN cohorts, which may indicate a difference in clinical presentations.

show abstract

A blind spot in urology: Prostate cancer associated retinopathy

Cited by 5 publications

References 5 publications

Blindness paving the path to the diagnosis of metastatic prostate carcinoma: A unique case presentation

Blindness paving the path to the diagnosis of metastatic prostate carcinoma: A unique case presentation

Review of Autoimmune Retinopathy and Its Association with Melanoma and Other Malignancies

Metastatic Prostate Cancer to the Optic Canal: A Large-Cohort Analysis

Contact Info

Product

Resources

About